Factor structure of the Subjective Well-being under Neuroleptic treatment Scale-short form in schizophrenic outpatients: Five factors or only one?

References

• Naber D. Subjective effects of antipsychotic treatment. Acta Psychiatr Scand 2005;111:81–3.
   Web of Science ®Google Scholar
• Naber D, Moritz S, Lambert F, Rajon R, Holzbach R, Mass B, et al. Improvement of schizophrenic patients’ subjective well- being under atypical antipsychotic drugs. Schizophr Res 2001;50:79–81.
   PubMed Web of Science ®Google Scholar
• Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad AG. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000;43:135–145.
   PubMed Web of Science ®Google Scholar
• Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res 2007;91:178–86.
   PubMed Web of Science ®Google Scholar
• Naber D, Walther A, Kircher T, Hayek D, Holzbach R. Subjective effects of neuroleptics predict adherence. In: Gaebel W, Awad AG, editors. Prediction of neuroleptic treatment outcome in schizophrenia: Concepts and methods. Vienna: Springer, 1994:85–98.
   Google Scholar
• Karow A, Schäfer I, Hirdes F, Osterwald C, Naber D. Subjective view of positive symptoms and quality of life in patients with schizophrenia. Psychiatr Prax 2008;35:286– 93.
   Google Scholar
• Putzhammer A, Perfahl M, Pfeiff L, Hajak G. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status. Pharmacopsychiatry 2005;38:132–8.
   PubMed Web of Science ®Google Scholar
• Karow A, Czekalla J, Dittmann RW, Schacht A, Wagner T, Lambert M, et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 2007;68:75–80.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Suzuki S, Uchida H, Nakajima S, Nomura K, Kikuchi T, et al. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia. Add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. J Clin Psychopharmacol 2008;28:540–3.
   Google Scholar
• Chino B, Nemoto T, Fujii C, Mizuno M. Subjective assessments of the quality of life, well-being and self-efficacy in patients with schizophrenia. Psychiatry Clin Neurosc 2009;63:521–8.
   Web of Science ®Google Scholar
• Lambert M, Naber D, Eich FX, Schacht M, Linden M, Schimmelmann BG. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand 2007;115:106–13.
   PubMed Web of Science ®Google Scholar
• Naber D, Karow A, Lambert M. Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand 2005;111 Suppl 427:29–34.
   Google Scholar
• Schennach-Wolff R, Jäger M, Obermeier M, Schmauss M, Laux G, Pfeiffer H, et al. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: Valid predictors of symptomatic response and remission?World J Biol Psychiatry 2010;11:729–38.
   PubMed Web of Science ®Google Scholar
• Vothknecht S, Schoevers RA, de Haan L. Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: A review. Aust NZ J Psychiat 2011;45:182–92.
   PubMed Web of Science ®Google Scholar
• Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psycholpharmacol 1995;10 Suppl 3:133–8.
   Google Scholar
• Guo J, Zhao Z, Ha S. Testing the reliability and Validity of Chinese Version of Subjective Well-being under Neuroleptics (SWN) Short Form. Med J Chin People Health 2003;15:1–2.
   Google Scholar
• Sanjuan J, Haro JM, Maurino J, Diez T, Ballesteros J. Validation of the Spanish version of the Subjective Well-being under Neuroleptic Scale (SWN) in patients with schizophrenia. Eur Psychiat 2010;25 Suppl 1:1103.
   Google Scholar
• Siamouli M, Moutou K, Pantoula E, Magiria S, Chatzivasileiou I, Arapidis K, et al. Preliminary data concerning the reliability and psychometric properties of the Greek translation of the 20-item Subjective Well-Being under Neuroleptic Treatment Scale (SWN-20). Ann Gen Psychiatry 2009;21:1–8.
   Google Scholar
• Yoon JS, Kook SH, Lee HY, Lee C, Paik IH. The Development of a Korean modification of the Scale to Measure Subjective Well-Being under Neuroleptic Treatment (KmSWN). J Korean Neuropsychiatr Assoc 2000;39:987–98.
   Google Scholar
• Wehmeier PM, Kluge M, Schneider E, Schacht A, Wagner T, Schreiber W. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:703–12.
   PubMed Web of Science ®Google Scholar
• Balestrieri M, Giaroli G, Mazzi M, Bellantuono C. Performance of the Italian version of the Subjective Well-being under Neuroleptic (SWN) Scale in Schizophrenic Outpatients. Pharmacopsychiatry 2006;39:81–4.
   Web of Science ®Google Scholar
• Mauriño J, Sanjúan J, Haro JM, Díez T, Ballesteros J. Impact of depressive symptoms on subjective well-being: The importance of patient-reported outcomes in schizophrenia. Patient Prefer Adherence 2011;5:471–4.
   Web of Science ®Google Scholar
• Vothknecht S, Meijer C, Zwinderman A, Kikkert M, Dekker J, van Beveren N, et al. Psychometric evaluation of the Subjective Well-being under Neuroleptic treatment Scale (SWN) in patients with schizophrenia, their relatives and controls. Psychiat Res 2012, http://dx.doi.org/10.1016/j.psychres.2012.09.004.
   Google Scholar
• Schmidt P, Clouth J, Haggenmüller L, Naber D, Reitberger U. Constructing an Index for the Subjective Well-being under Neuroleptics Scale (SWN), short form: Applying Structural Equation Modeling for testing reliability and validity of the index. Qual Life Res 2006;15:1191–202.
   Web of Science ®Google Scholar
• Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry 200;162:441–9.
   Google Scholar
• Marsh HW. Positive and negative global self-esteem: A substantively meaningful distinction or artifacts?. J Pers Soc Psychol 1996;70:810–9.
   PubMed Web of Science ®Google Scholar
• Marsh HW, Scalas LF, Nagengast B. Longitudinal tests of competing factor structures for the Rosenberg Self-Esteem Scale: Traits, ephemeral artifacts, and stable response styles. Psychol Assess 2010;22:366–81.
   PubMed Web of Science ®Google Scholar
• Joreskog KG, Sorbom D. LISREL 8.72. Lincolnwood, IL: Scientific Software International, Inc.; 2005.
   Google Scholar
• Kline RB. Principles and practice of Structural Equation Modeling. New York: The Guilford Press; 2005.
   Google Scholar
• Finlay WML, Lyons E. Acquiescence in interviews with people who have mental retardation. Ment Retard 2002;40:14–29.
   PubMedGoogle Scholar
• Dickinson D, Iannone VN, Wilk CM, James M, Gold JM. General and Specific Cognitive Deficits in Schizophrenia. Biol Psychiatry 2004;55:826–833.
   PubMed Web of Science ®Google Scholar
• Fioravanti M, Carlone O, Vitale B, Cinti ME, Clare N. A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol Rev 2005;15:73–9.
   PubMed Web of Science ®Google Scholar